 Juan Idrovo
Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 10 | 2025 | 325 | 4.420 |
Why?
| | Liver Diseases | 2 | 2021 | 315 | 1.100 |
Why?
| | Liver | 4 | 2025 | 1943 | 1.040 |
Why?
| | Reperfusion Injury | 3 | 2015 | 279 | 1.010 |
Why?
| | Mitochondria, Liver | 1 | 2025 | 73 | 0.900 |
Why?
| | 4-Butyrolactone | 2 | 2015 | 21 | 0.860 |
Why?
| | Aminoimidazole Carboxamide | 2 | 2015 | 12 | 0.850 |
Why?
| | Hepatocytes | 1 | 2025 | 220 | 0.840 |
Why?
| | Wound Healing | 2 | 2016 | 331 | 0.780 |
Why?
| | Mitochondrial Proteins | 1 | 2025 | 257 | 0.770 |
Why?
| | Caspases | 1 | 2023 | 247 | 0.760 |
Why?
| | Inflammation | 3 | 2020 | 2837 | 0.750 |
Why?
| | Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8 | 0.680 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2020 | 14 | 0.670 |
Why?
| | Alcoholic Intoxication | 1 | 2019 | 68 | 0.600 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 373 | 0.580 |
Why?
| | Coronavirus Infections | 2 | 2020 | 364 | 0.580 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.570 |
Why?
| | Cytokines | 2 | 2025 | 2085 | 0.550 |
Why?
| | Transcriptome | 1 | 2023 | 971 | 0.520 |
Why?
| | Intestines | 2 | 2021 | 357 | 0.520 |
Why?
| | Mice | 11 | 2025 | 17787 | 0.500 |
Why?
| | Hepatic Insufficiency | 1 | 2015 | 4 | 0.480 |
Why?
| | Adrenomedullin | 1 | 2015 | 5 | 0.470 |
Why?
| | Carnitine O-Palmitoyltransferase | 2 | 2012 | 46 | 0.470 |
Why?
| | Ribonucleotides | 1 | 2015 | 26 | 0.470 |
Why?
| | Lipogenesis | 1 | 2015 | 61 | 0.460 |
Why?
| | Aging | 2 | 2025 | 1864 | 0.460 |
Why?
| | Animals | 16 | 2025 | 36940 | 0.460 |
Why?
| | Complement Factor H | 1 | 2015 | 80 | 0.430 |
Why?
| | Shock, Hemorrhagic | 1 | 2016 | 167 | 0.420 |
Why?
| | Skin | 2 | 2016 | 752 | 0.420 |
Why?
| | Pandemics | 2 | 2020 | 1639 | 0.380 |
Why?
| | Ribonucleosides | 1 | 2012 | 6 | 0.380 |
Why?
| | Age Factors | 4 | 2025 | 3295 | 0.380 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2011 | 39 | 0.370 |
Why?
| | RNA-Binding Proteins | 1 | 2016 | 422 | 0.370 |
Why?
| | Renal Circulation | 1 | 2011 | 58 | 0.370 |
Why?
| | Acute Lung Injury | 1 | 2015 | 287 | 0.370 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 840 | 0.370 |
Why?
| | Renal Artery | 1 | 2011 | 37 | 0.370 |
Why?
| | Carnitine | 1 | 2012 | 84 | 0.360 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 496 | 0.360 |
Why?
| | Arterial Occlusive Diseases | 1 | 2011 | 83 | 0.350 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 5757 | 0.340 |
Why?
| | Energy Metabolism | 2 | 2012 | 922 | 0.300 |
Why?
| | Sepsis | 1 | 2015 | 617 | 0.300 |
Why?
| | Aspartate Aminotransferases | 2 | 2021 | 90 | 0.290 |
Why?
| | Rats, Sprague-Dawley | 4 | 2015 | 2486 | 0.280 |
Why?
| | Alanine Transaminase | 2 | 2021 | 157 | 0.280 |
Why?
| | Recovery of Function | 1 | 2012 | 653 | 0.280 |
Why?
| | Kidney | 2 | 2012 | 1468 | 0.270 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2020 | 1242 | 0.260 |
Why?
| | Apoptosis | 3 | 2025 | 2553 | 0.260 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4295 | 0.250 |
Why?
| | Median Arcuate Ligament Syndrome | 1 | 2025 | 8 | 0.240 |
Why?
| | Celiac Artery | 1 | 2025 | 17 | 0.240 |
Why?
| | Cough | 3 | 2020 | 122 | 0.230 |
Why?
| | Serum Amyloid A Protein | 1 | 2025 | 33 | 0.230 |
Why?
| | Kidney Transplantation | 1 | 2011 | 708 | 0.230 |
Why?
| | Intestinal Mucosa | 3 | 2021 | 623 | 0.230 |
Why?
| | Rats | 4 | 2015 | 5647 | 0.230 |
Why?
| | Fever | 3 | 2020 | 306 | 0.220 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 815 | 0.220 |
Why?
| | Dysbiosis | 2 | 2023 | 181 | 0.220 |
Why?
| | Neovascularization, Physiologic | 2 | 2016 | 179 | 0.220 |
Why?
| | Gene Silencing | 1 | 2025 | 195 | 0.210 |
Why?
| | Interleukin-6 | 2 | 2020 | 778 | 0.210 |
Why?
| | Robotic Surgical Procedures | 1 | 2025 | 130 | 0.210 |
Why?
| | Caspase 9 | 1 | 2023 | 57 | 0.210 |
Why?
| | Peroxidase | 2 | 2015 | 175 | 0.200 |
Why?
| | STAT3 Transcription Factor | 1 | 2025 | 206 | 0.200 |
Why?
| | Fluorouracil | 1 | 2023 | 208 | 0.190 |
Why?
| | Travel | 2 | 2020 | 130 | 0.190 |
Why?
| | Caspase 3 | 1 | 2023 | 246 | 0.190 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 622 | 0.180 |
Why?
| | Delirium | 1 | 2023 | 92 | 0.180 |
Why?
| | Dyspnea | 2 | 2020 | 254 | 0.180 |
Why?
| | Cell Survival | 1 | 2025 | 1120 | 0.180 |
Why?
| | Tight Junctions | 1 | 2021 | 76 | 0.180 |
Why?
| | Malondialdehyde | 1 | 2021 | 29 | 0.180 |
Why?
| | Human papillomavirus 16 | 1 | 2021 | 35 | 0.180 |
Why?
| | Lipid Peroxidation | 1 | 2021 | 153 | 0.170 |
Why?
| | Chemokine CXCL1 | 1 | 2020 | 76 | 0.170 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2021 | 83 | 0.170 |
Why?
| | Astrocytes | 1 | 2022 | 210 | 0.170 |
Why?
| | Papillomaviridae | 1 | 2021 | 125 | 0.170 |
Why?
| | Blood Cell Count | 1 | 2020 | 55 | 0.170 |
Why?
| | Resistin | 1 | 2019 | 11 | 0.160 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2019 | 14 | 0.160 |
Why?
| | Ghrelin | 1 | 2019 | 36 | 0.160 |
Why?
| | China | 1 | 2020 | 217 | 0.160 |
Why?
| | Adenosine Triphosphate | 2 | 2012 | 491 | 0.160 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2019 | 86 | 0.160 |
Why?
| | Male | 9 | 2025 | 67762 | 0.150 |
Why?
| | Glutathione | 1 | 2021 | 356 | 0.150 |
Why?
| | Interleukin-1beta | 1 | 2020 | 372 | 0.150 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2019 | 135 | 0.140 |
Why?
| | Gastrointestinal Tract | 1 | 2020 | 195 | 0.140 |
Why?
| | Female | 8 | 2025 | 73304 | 0.140 |
Why?
| | Oxidative Stress | 1 | 2025 | 1317 | 0.140 |
Why?
| | Leptin | 1 | 2019 | 236 | 0.140 |
Why?
| | Models, Animal | 1 | 2019 | 384 | 0.140 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1272 | 0.140 |
Why?
| | Humans | 15 | 2025 | 137585 | 0.130 |
Why?
| | Adenocarcinoma | 1 | 2023 | 940 | 0.120 |
Why?
| | Respiratory Tract Infections | 1 | 2020 | 390 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 807 | 0.120 |
Why?
| | Gene Expression Profiling | 1 | 2023 | 1774 | 0.120 |
Why?
| | Microbiota | 1 | 2023 | 762 | 0.120 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2015 | 122 | 0.120 |
Why?
| | Bacterial Load | 1 | 2015 | 68 | 0.110 |
Why?
| | Ethanol | 1 | 2019 | 608 | 0.110 |
Why?
| | Neutrophil Infiltration | 1 | 2015 | 107 | 0.110 |
Why?
| | Lung | 2 | 2020 | 4060 | 0.110 |
Why?
| | Influenza, Human | 1 | 2020 | 622 | 0.110 |
Why?
| | Hospitalization | 2 | 2020 | 2199 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 697 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2025 | 10811 | 0.100 |
Why?
| | Lymph Nodes | 1 | 2015 | 491 | 0.100 |
Why?
| | Aged | 5 | 2023 | 23961 | 0.090 |
Why?
| | Spasm | 1 | 2011 | 20 | 0.090 |
Why?
| | Edema | 1 | 2012 | 130 | 0.090 |
Why?
| | Gallbladder Neoplasms | 1 | 2011 | 23 | 0.090 |
Why?
| | Ligands | 2 | 2023 | 664 | 0.090 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 245 | 0.090 |
Why?
| | Leukocytes | 1 | 2012 | 311 | 0.090 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2011 | 87 | 0.080 |
Why?
| | Blood Flow Velocity | 1 | 2011 | 413 | 0.080 |
Why?
| | Blood Glucose | 1 | 2019 | 2186 | 0.080 |
Why?
| | Living Donors | 1 | 2011 | 295 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1238 | 0.080 |
Why?
| | Insulin | 1 | 2019 | 2409 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1066 | 0.070 |
Why?
| | Fatty Acids | 1 | 2012 | 443 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2253 | 0.070 |
Why?
| | Signal Transduction | 1 | 2020 | 5079 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2031 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 10388 | 0.060 |
Why?
| | Operative Time | 1 | 2025 | 145 | 0.060 |
Why?
| | Biomarkers | 1 | 2015 | 4149 | 0.050 |
Why?
| | Glypicans | 1 | 2023 | 11 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.050 |
Why?
| | Chemokines | 1 | 2023 | 228 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 48 | 0.050 |
Why?
| | Occludin | 1 | 2021 | 11 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2025 | 15657 | 0.050 |
Why?
| | Permeability | 1 | 2021 | 161 | 0.050 |
Why?
| | Human papillomavirus 18 | 1 | 2021 | 16 | 0.040 |
Why?
| | Infectious Disease Incubation Period | 1 | 2020 | 4 | 0.040 |
Why?
| | Colon | 1 | 2023 | 282 | 0.040 |
Why?
| | Time Factors | 1 | 2011 | 6828 | 0.040 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 56 | 0.040 |
Why?
| | Influenza B virus | 1 | 2020 | 44 | 0.040 |
Why?
| | Pharyngitis | 1 | 2020 | 26 | 0.040 |
Why?
| | Organ Specificity | 1 | 2020 | 305 | 0.040 |
Why?
| | Influenza A virus | 1 | 2020 | 107 | 0.040 |
Why?
| | Adult | 3 | 2025 | 37929 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 2023 | 321 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2023 | 1509 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2023 | 801 | 0.040 |
Why?
| | Survival Analysis | 1 | 2020 | 1325 | 0.030 |
Why?
| | Hippocampus | 1 | 2022 | 895 | 0.030 |
Why?
| | Middle Aged | 3 | 2025 | 33479 | 0.030 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 325 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2021 | 1738 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 858 | 0.030 |
Why?
| | Homeostasis | 1 | 2020 | 621 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2475 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 3412 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1153 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2025 | 2654 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2020 | 1069 | 0.020 |
Why?
| | Prognosis | 1 | 2021 | 4030 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2828 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2691 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 13209 | 0.020 |
Why?
| | Adolescent | 1 | 2025 | 21513 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7635 | 0.010 |
Why?
|
|
Idrovo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|